Last: | $1.09 |
---|---|
Change Percent: | -0.99% |
Open: | $1.02 |
Close: | $1.09 |
High: | $1.11 |
Low: | $1.02 |
Volume: | 143,939 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.09 | $1.02 | $1.09 | $1.11 | $1.02 | 143,939 | 04-26-2024 |
$1.01 | $1.06 | $1.01 | $1.08 | $0.951 | 239,428 | 04-25-2024 |
$1.06 | $1.05 | $1.06 | $1.11 | $1.01 | 296,991 | 04-24-2024 |
$1.05 | $1.08 | $1.05 | $1.15 | $1.01 | 445,670 | 04-23-2024 |
$1.1 | $1.14 | $1.1 | $1.18 | $1.05 | 256,328 | 04-22-2024 |
$1.15 | $1.25 | $1.15 | $1.28 | $1.12 | 339,700 | 04-19-2024 |
$1.28 | $1.22 | $1.28 | $1.28 | $1.2 | 154,329 | 04-18-2024 |
$1.23 | $1.3 | $1.23 | $1.34 | $1.22 | 438,797 | 04-17-2024 |
$1.3 | $1.26 | $1.3 | $1.38 | $1.22 | 325,034 | 04-16-2024 |
$1.26 | $1.19 | $1.26 | $1.29 | $1.19 | 268,821 | 04-15-2024 |
$1.18 | $1.33 | $1.18 | $1.34 | $1.18 | 504,263 | 04-12-2024 |
$1.36 | $1.3 | $1.36 | $1.4 | $1.26 | 398,557 | 04-11-2024 |
$1.28 | $1.28 | $1.28 | $1.36 | $1.27 | 413,745 | 04-10-2024 |
$1.31 | $1.42 | $1.31 | $1.49 | $1.31 | 413,366 | 04-09-2024 |
$1.47 | $1.23 | $1.47 | $1.55 | $1.16 | 1,739,844 | 04-08-2024 |
$1.2 | $1.16 | $1.2 | $1.3 | $1.14 | 734,852 | 04-05-2024 |
$1.21 | $1.31 | $1.21 | $1.34 | $1.18 | 899,747 | 04-04-2024 |
$1.3 | $1.45 | $1.3 | $1.47 | $1.11 | 2,296,409 | 04-03-2024 |
$1.48 | $1.42 | $1.48 | $1.61 | $1.33 | 3,029,914 | 04-02-2024 |
$1.53 | $1.32 | $1.53 | $1.63 | $1.14 | 21,376,516 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Xilio Therapeutics Inc. Company Name:
XLO Stock Symbol:
NASDAQ Market:
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quar...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and ...